Alan J Bitonti

This inventor holds 43 USPTO granted patents and 17 published patent applications, plus 14 CIPO patents and 16 EPO patents, primarily in Chimeric Proteins. Top assignees: Syntonix Pharmaceuticals, Inc., Bioverativ Therapeutics Inc., Merrell Dow Pharmaceuticals. Active years: 1990-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Alan J Bitonti. Retrieved from https://idiyas.com/inventor/alan-j-bitonti

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 43 (Patent Applications = 17)

% Patents Active = 88.4

CIPO Patents = 14 (Patent Applications = 5)

EPO Patents = 16 (Patent Applications = 18)

Average Co-Inventor Count = 3.2

ph-index = 15

Forward Citations = 945(Granted Patents)

Location History:

Cincinnati, OH (US) (1997)
Maineville, OH (US) (1990 - 2000)
Ringoes, NJ (US) (2002)
Annapolis, MD (US) (2016)
Action, MA (US) (2017)
Acton, MA (US) (2002 - 2022)

Company Filing History:

10 out of 14

Syntonix Pharmaceuticals, Inc.

patents

8 out of 76

Bioverativ Therapeutics Inc.

patents

7 out of 455

Merrell Dow Pharmaceuticals

patents

4. 7 out of 194

Merrell Pharmaceuticals, Inc.

patents

5. 3 out of 207

Aventis Pharmaceuticals Inc.

patents

6. 3 out of 5

Biogen Idec Hemophilia Inc.

Biogen Hemophilia Inc.

patents

9. 2 out of 236

Hoechst Marion Roussel

patents

10. 1 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1990-2025

Loading Chart...

Areas of Expertise:

Chimeric Proteins

Factor VIII

Immunoglobulin

Clotting Factors

Fc Receptor

Antibodies

Peptides

Cancer Treatment

Triaryl-Ethylene

Polyamine Derivatives

Estrogen-Related Neoplasms

Malarial Infections

43 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12186375 - Factor VIII chimeric and hybrid polypeptides, and methods of use thereof (2025-01-07),

2. 11401322 - Immunoglobulin chimeric monomer-dimer hybrids (2022-08-02),

3. 11266720 - Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof (2022-03-08),

4. 11168125 - Immunoglobulin chimeric monomer-dimer hybrids (2021-11-09),

5. 10968442 - Chimeric clotting factors (2021-04-06),

6. 10881742 - Factor VIII chimeric and hybrid polypeptides, and methods of use thereof (2021-01-05),

7. 10023628 - Cell line expressing single chain factor VIII polypeptides and uses thereof (2018-07-17),

8. 9725496 - Immunoglobulin chimeric monomer-dimer hybrids (2017-08-08),

9. 9260520 - Antibodies to FeRn and uses thereof (2016-02-16),

10. 9241978 - Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof (2016-01-26),

11. 9050318 - Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof (2015-06-09),

12. 8932830 - Immunoglobulin chimeric monomer-dimer hybrids (2015-01-13),

13. 8815250 - Clotting factor-Fc chimeric proteins to treat hemophilia (2014-08-26),

14. 8815246 - Fc receptor binding proteins (2014-08-26),

15. 8449884 - Clotting factor-fc chimeric proteins to treat hemophilia (2013-05-28),

Title: The Innovative Mind of Alan J Bitonti: Revolutionizing the Biotechnology Industry

Introduction: Alan J Bitonti, a brilliant inventor hailing from Acton, MA, has left an indelible mark on the field of biotechnology with his impressive portfolio of 25 patents.

Latest Patents: Alan's recent patents include groundbreaking inventions such as the Immunoglobulin chimeric monomer-dimer hybrids and Factor VIII-FC chimeric and hybrid polypeptides. These innovations have paved the way for novel methods in protein engineering and biopharmaceuticals.

Career Highlights: Throughout his career, Alan J Bitonti has made significant contributions to the biotechnology sector. He has worked with esteemed companies like Syntonix Pharmaceuticals, Inc. and Bioverativ Therapeutics Inc., where his inventive spirit thrived.

Collaborations: Alan has collaborated closely with talented individuals in the field, such as Robert T Peters and Susan C Low. Their combined efforts have led to the development of cutting-edge technologies that have reshaped the landscape of biopharmaceutical research.

Conclusion: Alan J Bitonti's dedication to innovation and relentless pursuit of scientific excellence have positioned him as a trailblazer in the realm of biotechnology. His patents stand as a testament to his ingenuity and unwavering commitment to pushing the boundaries of what is possible in the field.

Profile summary based on public USPTO records.